| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Corradini, M., et al.
(författare)
-
Experimental apparatus for annihilation cross-section measurements of low energy antiprotons
- 2013
-
Ingår i: Nuclear Instruments and Methods in Physics Research Section A. - : Elsevier BV. - 0168-9002 .- 1872-9576. ; 711, s. 12-20
-
Tidskriftsartikel (refereegranskat)abstract
- The nuclear physics program of the ASACUSA experiment at the Antiproton Decelerator (AD) at CERN is concerned with the measurements of antiproton-nuclei cross-sections at low energies (from 5.3 MeV down to the 100 keV region). These measurements are expected to contribute to understand the dynamics of the annihilation process. We give here a full description of the experimental apparatus used for the measurements at 5.3 MeV. © 2013 Elsevier B.V.
|
|
| 6. |
- Fung, P. P. L., et al.
(författare)
-
Time to onset of bisphosphonate-related osteonecrosis of the jaws : a multicentre retrospective cohort study
- 2017
-
Ingår i: Oral Diseases. - : WILEY. - 1354-523X .- 1601-0825. ; 23:4, s. 477-483
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients.Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012.Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n=88) and 2.2years in those treated with zoledronate (n=218). Multivariable Cox regression showed that dentoalveolar surgery was inversely associated, and the use of antiangiogenics directly associated, with the TTO in patients with cancer treated with zoledronate.Conclusions: The incidence of ONJ increases with the duration of BP therapy, with notable differences observed with respect to BP type and potency, route of administration and underlying disease. When data are stratified by BP type, a time of 6.0 and 2.2years of oral alendronate and intravenous zoledronate therapy, respectively, is required for 50% of patients to develop ONJ. After stratification by disease, a time of 5.3 and 2.2years of BP therapy is required for 50% of patients with osteoporosis and cancer, respectively, to develop ONJ. These findings have significant implications for the design of future clinical studies and the development of risk-reduction strategies aimed at either assessing or modulating the risk of ONJ associated with BP.
|
|
| 7. |
|
|
| 8. |
- Ning, Lixin, et al.
(författare)
-
Theoretical study ofI-4(13/2) -> I-4(15/2) luminescence quenching by OH for LaF3 : Er3+ nanoparticles in solution
- 2007
-
Ingår i: Journal of Physics. - : IOP Publishing. - 0953-8984 .- 1361-648X. ; 19:1
-
Tidskriftsartikel (refereegranskat)abstract
- The processes of I-4(13/2)-> I-4(15/2) luminescence quenching by OH vibrations are investigated for LaF3:Er3+ nanoparticles dissolved in solution. The energy transfer (ET) rates, involving the I-4(13/2)-> I-4(15/2) transition of Er3+ and the first overtone absorption of OH, are estimated. In order to calculate the relevant OH transition matrix elements, a model for the OH vibration in solution is developed with the use of a Morse potential. Various multipole-multipole ET mechanisms are considered and their dependences on the distance between Er3+ and OH are studied. Based on these ET mechanisms, the ET rates from an Er3+ in the nanoparticle to all the OH in solution are estimated and compared with respect to changes in location of the ion, size of the nanoparticle and OH concentration in solution. The effective I-4(13/2)-> I-4(15/2) luminescence decay times that are contributed by all the Er3+ in the nanoparticle are then calculated with different Er3+ concentrations. The calculations satisfactorily account for experimental observations.
|
|
| 9. |
- Pellegrini, C, et al.
(författare)
-
A Meta-Analysis of Brain DNA Methylation Across Sex, Age, and Alzheimer's Disease Points for Accelerated Epigenetic Aging in Neurodegeneration
- 2021
-
Ingår i: Frontiers in aging neuroscience. - : Frontiers Media SA. - 1663-4365. ; 13, s. 639428-
-
Forskningsöversikt (övrigt vetenskapligt/konstnärligt)abstract
- Alzheimer's disease (AD) is characterized by specific alterations of brain DNA methylation (DNAm) patterns. Age and sex, two major risk factors for AD, are also known to largely affect the epigenetic profiles in brain, but their contribution to AD-associated DNAm changes has been poorly investigated. In this study we considered publicly available DNAm datasets of four brain regions (temporal, frontal, entorhinal cortex, and cerebellum) from healthy adult subjects and AD patients, and performed a meta-analysis to identify sex-, age-, and AD-associated epigenetic profiles. In one of these datasets it was also possible to distinguish 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiles. We showed that DNAm differences between males and females tend to be shared between the four brain regions, while aging differently affects cortical regions compared to cerebellum. We found that the proportion of sex-dependent probes whose methylation is modified also during aging is higher than expected, but that differences between males and females tend to be maintained, with only a few probes showing age-by-sex interaction. We did not find significant overlaps between AD- and sex-associated probes, nor disease-by-sex interaction effects. On the contrary, we found that AD-related epigenetic modifications are significantly enriched in probes whose DNAm varies with age and that there is a high concordance between the direction of changes (hyper or hypo-methylation) in aging and AD, supporting accelerated epigenetic aging in the disease. In summary, our results suggest that age-associated DNAm patterns concur to the epigenetic deregulation observed in AD, providing new insights on how advanced age enables neurodegeneration.
|
|
